Nephros, Inc.
NEPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.00 | 0.29 | -0.02 | 0.68 |
| FCF Yield | -3.54% | 2.09% | -28.22% | -2.46% |
| EV / EBITDA | 57.81 | -24.62 | -2.55 | -21.33 |
| Quality | ||||
| ROIC | 0.05% | -14.97% | -43.46% | -20.55% |
| Gross Margin | 61.59% | 59.03% | 47.43% | 55.13% |
| Cash Conversion Ratio | -6.65 | -0.53 | 0.71 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.39% | 11.70% | 5.23% | -0.38% |
| Free Cash Flow Growth | -172.74% | 122.31% | -132.00% | 79.66% |
| Safety | ||||
| Net Debt / EBITDA | -10.35 | 1.82 | 0.69 | 2.40 |
| Interest Coverage | 6.00 | -796.50 | -216.75 | -79.32 |
| Efficiency | ||||
| Inventory Turnover | 2.08 | 2.36 | 1.66 | 1.03 |
| Cash Conversion Cycle | 177.84 | 138.28 | 215.01 | 307.69 |